Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

BALTIMORE, MD, December 3, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic ...

Today, Industry Dive, the company behind BioPharma Dive, is combining with TechTarget’s technology websites and Informa ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...